Corcept to Present New Data from Phase 3 ROSELLA Trial on Relacorilant for Platinum-Resistant Ovarian Cancer at ESMO

Summary

Corcept Therapeutics will present new data from its pivotal Phase 3 ROSELLA trial on relacorilant for platinum-resistant ovarian cancer at the ESMO Annual Meeting in 2025. The trial focuses on patients previously treated with a PARP inhibitor and will share findings during a late-breaking session on October 19, 2025.Reuters

Impact Analysis

So basically, Corcept is gearing up to make a splash at the ESMO Annual Meeting with their Phase 3 ROSELLA trial data on relacorilant. This isn’t just about showcasing results; it’s a strategic play to strengthen their position before the FDA’s PDUFA date in July 2026. The timing is key—presenting at a high-profile event like ESMO can generate buzz and potentially sway market sentiment positively. The trial’s focus on patients previously treated with a PARP inhibitor adds a layer of complexity and potential differentiation in the competitive landscape of ovarian cancer treatments. While the market has already rated CORT stock as a Buy, the real question is whether this data will exceed expectations and justify the $79 price target. Watch for any unexpected efficacy or safety data that could shift the narrative. The market might be underestimating the impact of this presentation on Corcept’s valuation and future revenue streams.Reuters+ 2